专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016028503A1 THERAPY FOR FILOVIRUS INFECTION 审中-公开
标题翻译：治疗FILOVIRUS感染
公开(公告)号：WO2016028503A1
公开(公告)日：2016-02-25
申请号：PCT/US2015/043927
申请日：2015-08-06
申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. , THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO , U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND
发明人： LAI, Jonathan, R. , KOELLHOFFER, Jayne, F. , FREI, Julia , CHANDRAN, Kartik , SIDHU, Sachdev , CHEN, Gang , DYE, John, M. , ZAK, Samantha
IPC分类号： C07K16/10
CPC分类号： C07K16/10 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76
摘要： The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.
摘要翻译：本发明解决了对改善的病毒感染治疗的需要。本发明提供分离的人源化抗病毒糖蛋白预融合核心抗体，其包含与人抗体框架区具有95％或更高同一性的序列的框架区。还提供了治疗和/或抑制受试者中的病毒感染的方法，其包括向受试者施用一定量的本文所述的任何抗体或其抗原结合片段的量。还提供了包含本文所述的任何抗体的组合物或其一定量的抗原结合片段。在一个实施方案中，组合物包含药学上可接受的载体。

2. 发明申请

WO2001079546A3 FLAVIVIRUS DETECTION AND QUANTIFICATION ASSAY 审中-公开
公开(公告)号：WO2001079546A3
公开(公告)日：2001-10-25
申请号：PCT/US2000/028961
申请日：2000-10-19
申请人： U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND , HOUNG, Huo-Shu, H. , KANESA-THASAN, Niranjan
发明人： HOUNG, Huo-Shu, H. , KANESA-THASAN, Niranjan
IPC分类号： C12Q1/68
摘要： Fluorescent DNA probes specific and flanking primer pairs are designed based on the sequence information found in the conserved terminal 3'-noncoding region of flavivirus, e.g. nucleotides 10653-10678 of dengue virus. Fluorogenic polymerase chain reaction employing these primers and probes produce results that permit specific flavivirus identification. The assays can be both quantitative and qualitative. Optimal assay conditions with zero background are disclosed which permit the detection of low levels of flavivirus from clinical specimens. Specifically, Dengue virus isolates from different geographic regions can be universally detected and identified by the disclosed fluorogenic RT-PCR assay. The fluorogenic RT-PCR assay readily detected viremia in sera collected from individuals ill with dengue fever.

3. 发明申请

WO1996016643A1 DRUG RELEASING SURGICAL IMPLANT OR DRESSING MATERIAL 审中-公开
标题翻译：药物释放外科植入物或衣服材料
公开(公告)号：WO1996016643A1
公开(公告)日：1996-06-06
申请号：PCT/US1995014559
申请日：1995-11-28
申请人： PHARMA-LOGIC, INC. , U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND
发明人： PHARMA-LOGIC, INC. , U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND , HAYNES, Duncan, H. , BOEDEKER, Ben, H. , KLINE, Mark, D.
IPC分类号： A61K09/70
CPC分类号： A61K9/0024 , A61K9/70 , A61L15/425 , A61L15/44 , A61L15/46 , A61L15/64 , A61L27/54 , A61L27/56 , A61L27/58 , A61L2300/402 , A61L2300/404 , A61L2300/406 , A61L2300/41 , A61L2300/412 , A61L2300/602 , A61L2300/622 , Y10S977/801 , Y10S977/906 , Y10S977/915 , Y10T442/2525
摘要： A surgical implant or external wound dressing which functions as both a hemostat and a device to safely and effectively deliver any of a number of pharmaceuticals to targeted tissue at a controlled rate is disclosed. The device generally comprises a carrier in the form of fibers, sutures, fabrics, cross-linked solid foams or bandages, a pharmaceutical in solid microparticulate form releasably bound to the carrier fibers, and a lipid adjuvant which aids the binding of the microparticles to the fibers as well as their function in the body.
摘要翻译：公开了用作止血剂和用于以受控速率安全且有效地将任何多种药物递送到靶组织的手术植入物或外部伤口敷料。该装置通常包括纤维，缝线，织物，交联固体泡沫或绷带形式的载体，可释放地结合到载体纤维的固态微粒形式的药物，以及有助于将微粒结合到纤维以及它们在体内的功能。

4. 发明申请

WO2010144102A1 PENTAFLUOROSULFANYL ANALOGS OF MEFLOQUINE 审中-公开
标题翻译：。。。。。。。。。。。。。。
公开(公告)号：WO2010144102A1
公开(公告)日：2010-12-16
申请号：PCT/US2009/055799
申请日：2009-09-02
申请人： THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY, on behalf of U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND , DOW, Geoffrey, S. , MILNER, Erin, E. , WIPF, Peter , MO, Tingting
发明人： DOW, Geoffrey, S. , MILNER, Erin, E. , WIPF, Peter , MO, Tingting
IPC分类号： A01N43/42 , A61K31/47 , C07D215/12
CPC分类号： A61K31/47 , A01N43/42 , A01N43/50 , A01N43/60 , A01N43/647 , A01N43/66 , C07D215/12 , C07D401/06 , C07D409/12 , C07D453/00 , Y02A50/411
摘要： The present invention relates to new mefloquine derivatives and therapeutic compositions comprising one or more mefloquine derivatives. Mefloquine derivatives of the invention have at least one pentafluorosulfanyl moiety substitution at the 6 or 7 or 8 position. Certain mefloquine derivatives further include a quinoline methonal moiety substitution at the 4 position. These compositions are useful in the reduction, treatment, or prevention of malaria, microbial, parasitic, protozoan, bacterial, and fungal diseases and conditions. Advantageously, compositions of the invention are less able to cross the blood-brain barrier than mefloquine and as a result produce fewer adverse side effects to the central nervous system as compared to mefloquine.
摘要翻译：本发明涉及新的甲氟喹衍生物和包含一种或多种甲氟喹衍生物的治疗组合物。本发明的甲氟喹衍生物在6或7或8位具有至少一个五氟硫烷基取代。某些甲氟喹衍生物还包括在4位上的喹啉甲基取代。这些组合物可用于减少，治疗或预防疟疾，微生物，寄生虫，原生动物，细菌和真菌疾病和病症。有利地，本发明的组合物比甲氟喹较少能够穿过血脑屏障，因此与甲氟喹相比，对中枢神经系统的不良副作用较少。

5. 发明申请

WO2003069303A3 ANTIMALARIAL AND ANTIPROLIFERATIVE PHARMACOPHORE MODELS, NOVEL TRYPTANTHRIN COMPOUNDS HAVING INCREASED SOLUBILITY, AND METHODS OF MAKING AND USING THEREOF 审中-公开
公开(公告)号：WO2003069303A3
公开(公告)日：2003-08-21
申请号：PCT/US2003/003517
申请日：2003-02-07
申请人： U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND , NICHOLS, Daniel, A. , HICKS, Rickey, P. , BHATTACHARJEE, Apurba, K.
发明人： NICHOLS, Daniel, A. , HICKS, Rickey, P. , BHATTACHARJEE, Apurba, K.
IPC分类号： A61K31/517
摘要： Disclosed herein is a pharmacophore model for antimalarial activity and methods of making and using thereof. The pharmacophore comprises two hydrogen bond acceptor (lipid) functions and two hydrophobic (aromatic) functions. The pharmacophore model was made using a test set of tryptanthrin compounds which exhibit antimalarial activity. Also disclosed are tryptanthrin compounds having greater solubility and bioactivity as compared to prior art tryptanthrin compounds and methods of making and using thereof. Also disclosed are methods of treating malaria in a subject.

6. 发明申请

WO2003068736A3 MIXED STEROIDAL 1,2,4,5-TETRAOXANE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF 审中-公开
公开(公告)号：WO2003068736A3
公开(公告)日：2003-08-21
申请号：PCT/US2003/003516
申请日：2003-02-07
申请人： U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND , SOLAJA, Bogdan , MILHOUS, Wilbur , OPSENICA, Dejan, M. , POCSFALVI, Gabriella , KYLE, Dennis, E.
发明人： SOLAJA, Bogdan , MILHOUS, Wilbur , OPSENICA, Dejan, M. , POCSFALVI, Gabriella , KYLE, Dennis, E.
IPC分类号： A01N45/00
摘要： Disclosed herein are mixed steroidal tetraoxanes having the following structural Formula (I), wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, methyl, or ethyl; R4 is H, methyl, ethyl, tert -butyl, phenyl, p -hydroxyphenyl, p -methoxyphenyl, or p -nitrophenyl, or Formula (a), wherein Y is C 1 -C 4 straight or branched-chain alkoxy, or Formula (b), wherein W is N, R5 is hydrogen, methyl, ethyl, or n -propyl, isopropyl, or methyl ethanoate 2-yl, and R6 is hydrogen, methyl, ethyl, or n -propyl, or R5 and R6 are part of a pyrrolidine or piperidine ring; X is a C 1 -C 4 straight or branched-chain alkoxy, a primary amino, a N -akylamino wherein the alkyl is a straight-chain alkyl groups containing from 1 to 4 carbon atoms, methyl ethanoate-2-yl, N -phenylamino, p -nitrophenyl, N , N -dimethylamino, N , N -diethylamino, N , N -di( n -propyl)amino, N -pyrrolidino, or N -piperidino as single compounds, and any mixture of all possible stereoisomers at C(4’’). n may be 0, 1, 2, or 3, and methods of making and using thereof. As disclosed herein, the mixed steroidal tetraoxanes of the present invention exhibit antimalarial, antibacterial, and antiproliferative activity. Thus, as disclosed herein, the mixed steroidal tetraoxanes of the present invention may be used to treat, prevent, or inhibit malaria, bacterial infections, and diseases and disorders associated with cell proliferation in a subject.

7. 发明申请

WO2003068736A2 MIXED STEROIDAL 1,2,4,5-TETRAOXANE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF 审中-公开
标题翻译：混合固体1,2,4,5-四氯乙烯化合物及其制备和使用方法
公开(公告)号：WO2003068736A2
公开(公告)日：2003-08-21
申请号：PCT/US2003/003516
申请日：2003-02-07
申请人： U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND , SOLAJA, Bogdan , MILHOUS, Wilbur , OPSENICA, Dejan, M. , POCSFALVI, Gabriella , KYLE, Dennis, E.
发明人： SOLAJA, Bogdan , MILHOUS, Wilbur , OPSENICA, Dejan, M. , POCSFALVI, Gabriella , KYLE, Dennis, E.
IPC分类号： C07D
CPC分类号： C07J21/00 , C07J41/0061
摘要： Disclosed herein are mixed steroidal tetraoxanes having the following structural Formula (I), wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, methyl, or ethyl; R4 is H, methyl, ethyl, tert -butyl, phenyl, p -hydroxyphenyl, p -methoxyphenyl, or p -nitrophenyl, or Formula (II), wherein Y is C 1 -C 4 straight or branched-chain alkoxy, or Formula (III), wherein W is N, R5 is hydrogen, methyl, ethyl, or n -propyl, isopropyl, or methyl ethanoate 2-yl, and R6 is hydrogen, methyl, ethyl, or n -propyl, or R5 and R6 are part of a pyrrolidine or piperidine ring; X is a C 1 -C 4 straight or branched-chain alkoxy, a primary amino, a N -akylamino wherein the alkyl is a straight-chain alkyl groups containing from 1 to 4 carbon atoms, methyl ethanoate-2-yl, N -phenylamino, p -nitrophenyl, N , N -dimethylamino, N , N -diethylamino, N , N -di( n -propyl)amino, N -pyrrolidino, or N -piperidino as single compounds, and any mixture of all possible stereoisomers at C(4’’). n may be 0, 1, 2, or 3, and methods of making and using thereof. As disclosed herein, the mixed steroidal tetraoxanes of the present invention exhibit antimalarial, antibacterial, and antiproliferative activity. Thus, as disclosed herein, the mixed steroidal tetraoxanes of the present invention may be used to treat, prevent, or inhibit malaria, bacterial infections, and diseases and disorders associated with cell proliferation in a subject.
摘要翻译：本文公开了具有以下结构式I的混合甾族四恶烷，其中n为0,1,2或3 R为H乙酰基，丙酰基或苯甲酰基，R 1为H，甲基，乙基或异丙基，R 2为H，甲基或乙基R 3为H，甲基或R 4为H，甲基，乙基，叔丁基，苯基，对羟基苯基，对甲氧基苯基或对硝基苯基或式II，其中Y为C 1 -C 4直链或支链，链烷氧基或式III，其中W是N，R 5是氢，甲基，乙基或正丙基，异丙基或甲基乙酸酯2-基，并且R 6是氢，甲基，乙基或正丙基，或R 5 并且R 6是吡咯烷或哌啶环的一部分，X是C 1 -C 4直链或支链烷氧基，伯氨基，N-烷基氨基，其中烷基是含有1至4个碳原子的直链烷基，甲基乙酸酯-2-基，N-苯基氨基，对硝基苯基，N，N-二甲基氨基，N，N-二乙基氨基，N，N-二 - 丙基氨基，N-吡咯烷子基或N-哌啶子基作为单一化合物，所有可能的立体声在C4“somers。 n可以是0,1,2或3，以及其制备和使用方法。如本文所公开的，本发明的混合甾族四恶烷显示抗疟疾，抗细菌和抗增殖活性。因此，如本文所公开的，本发明的混合甾族四恶烷可用于治疗，预防或抑制疟疾，细菌感染以及与受试者中细胞增殖相关的疾病和病症。

8. 发明申请

WO2005016353A1 TOPICAL OINTMENT FOR VESICATING CHEMICAL WARFARE AGENTS 审中-公开
标题翻译：化学品保护剂代用品的主题
公开(公告)号：WO2005016353A1
公开(公告)日：2005-02-24
申请号：PCT/US2004/000833
申请日：2004-01-14
申请人： U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND DEPARTMENT OF THE ARMY , ARROYO, Carmen, F. , BURMAN, Damon, L.
发明人： ARROYO, Carmen, F. , BURMAN, Damon, L.
IPC分类号： A61K31/593
CPC分类号： A61K31/593 , A61K9/0014 , A61K31/19
摘要： The regulatory effects of the active form of vitamin D, 1-α, 25-dihydroxyvitamin D 3 (1-α, 25(OH) 2 D 3 ) were assessed on the cytokine and chemokine secretion induced by sulfur mustard (HD) on human skin fibroblasts (HSF) and human epidermal keratinocytes (HEK). Stimulation of HSF with HD (10 -4 M for 24 hours at 37° C) resulted in about a 5-fold increase in the secretion of interleukin-6 (IL-6) and over a 10- fold increase for interleukin-8 (IL-8), which was inhibited by 1-α, 25(OH) 2 D 3 , at ≤ 10 -9 M. 1-α, 25(OH) 2 D 3 also suppressed IL-8 secretion by five-fold and IL-6 by four-fold on HD-stimulated HEK at concentrations ≤ 10 -9 M. The effect of 1-α, 25(OH) 2 D 3 was dose-dependent for the suppression of IL-6 and IL-8 induced by HD on HSF/HEK, apparent at nanomolar concentrations. Results indicate that the suppression of these inflammatory mediators by 1-α, 25(OH) 2 D 3 is dependent on the source of the primary cultures, cell densities, and kinetics of pretreatments. In addition, a composition for a topical ointment for wound healing in mammals exposed to vesicating chemical warfare agents is also disclosed. The composition includes a compound or the combination of a 1-α, 25(OH) 2 D 3 and shark liver oil. The steroid hormone 1-α, 25(OH) 2 D 3 (calcitriol), in addition to its crucial role in calcium homeostasis, provides benefits to the immune system by regulating cell proliferation, differentiation and maturation. These benefits are effectuated through the control of protooncogenes and the regulation of cytokine production.
摘要翻译：对维生素D，1-α，25-二羟基维生素D3（1-α，25（OH）2D3）的活性形式的调节作用对由硫芥末（HD）对人皮肤成纤维细胞诱导的细胞因子和趋化因子分泌进行评估 HSF）和人表皮角化细胞（HEK）。用HD（10 -4 M在37℃下刺激24小时）刺激HSF导致白介素-6（IL-6）分泌增加约5倍，白细胞介素-6 8（IL-8），其在1 =α，25（OH）2D3受1-α，25（OH）2D3的抑制，也抑制IL-8分泌5倍和IL-6在HD-刺激的HEK浓度<= 10 -9 M时为4倍。1-α，25（OH）2D3的作用对于抑制IL-6和IL- 8由HD在HSF / HEK上诱导，以纳摩尔浓度表现。结果表明，通过1-α，25（OH）2D3抑制这些炎症介质取决于原代培养的来源，细胞密度和预处理的动力学。此外，还公开了暴露于泡沫化学战剂的哺乳动物中用于伤口愈合的外用软膏组合物。组合物包括化合物或1-α，25（OH）2D3和鲨鱼肝油的组合。类固醇激素1-α，25（OH）2D3（骨化三醇）除了其在钙稳态中的关键作用外，通过调节细胞增殖，分化和成熟为免疫系统提供了益处。这些益处通过控制原癌基因和细胞因子产生的调节来实现。

9. 发明申请

WO2003048817A1 APERTURE STOP WITH LOW BACKSCATTERING 审中-公开
标题翻译：低背压的APERTURE停止
公开(公告)号：WO2003048817A1
公开(公告)日：2003-06-12
申请号：PCT/US2002/038225
申请日：2002-11-26
申请人： U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND , RASH, Clarence, E. , MORA, John, C.
发明人： RASH, Clarence, E. , MORA, John, C.
IPC分类号： G02B5/00
CPC分类号： G02B5/001 , G02B5/005
摘要： A system including but not limited to a low-backscatter aperture structure, where the system can include but is not limited to a camera, an optical communications system, an imaging system, a test system, and a measurement system.
摘要翻译：包括但不限于低反向散射孔结构的系统，其中系统可以包括但不限于照相机，光通信系统，成像系统，测试系统和测量系统。

10. 发明授权

US10435461B2 Therapy for filovirus infection 有权
公开(公告)号：US10435461B2
公开(公告)日：2019-10-08
申请号：US15327857
申请日：2015-08-06
申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. , THE GOVERNING COUNCEL OF THE UNIVERSITY OF TORONTO , U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND
发明人： Jonathan R. Lai , Jayne F. Koellhoffer , Julia Frei , Kartik Chandran , Sachdev Sidhu , Gang Chen , John M. Dye , Samantha Zak
IPC分类号： C07K16/10 , A61K39/00
摘要： The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式